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Strategies targeting T cells are the cornerstone of immunosuppression after solid
organ transplantation. The transcription factor NF-κB is a key regulator of downstream
T-cell activation and induction of inflammatory mediators; its full activation via antigen
receptor engagement requires both the scaffold and the protease activity of the
paracaspase Malt1. Experimental studies have highlighted that Malt1-deficient mice
were resistant to experimental autoimmune encephalomyelitis, although they lacked
peripheral regulatory T cells (Treg). Here, we compared targeting Malt1 versus using
calcineurin inhibitors as immunosuppression in a stringent experimental transplantation
model. We found that Malt1-deficiency impaired Th1-mediated alloresponses in vitro
and in vivo and significantly prolonged MHC-mismatched skin allograft survival,
compared to cyclosporine. However, it paradoxically enhanced Th17 differentiation in
the transplantation setting. Interestingly, more selective inhibition of Malt1 protease
activity in wild-type mouse and human peripheral T cells in vitro led to attenuation of
alloreactive Th1 cells, while preserving preexisting Treg in the peripheral T-cell pool, and
without promoting Th17 differentiation. Thus, there is a place for further investigation of
the role of Malt1 signaling in the setting of transplantation.
Keywords: transplantation, paracaspase, NF-kB, calcineurin inhibitors, regulatory T cells, Th17 cells
INTRODUCTION
CD4+ T cells play a central role in primary alloresponses after solid organ transplantation (SOT)
by providing effector cytokines and cognate help for cytotoxic CD8+ T lymphocytes and B-cell
activation. Graft rejection has been shown to be primarily a Th1-mediated immune response;
however, Th17- or Th2-mediated graft rejection has been observed, in particular in the absence
of a robust Th1 response (1–3). T-cell activation is regulated by a set of transcription factors
belonging to the nuclear factor kappa-B (NF-κB) and nuclear factor of activated T cells (NFAT)
families (4). The ligation of the T-cell receptor (TCR) by cognate antigens leads to increased levels
of intracellular calcium and activation of the calcium-dependent phosphatase enzyme calcineurin
that dephosphorylates NFAT. NFAT then translocates into the nucleus and binds to the enhancer
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of the gene encoding interleukin-2 (IL-2). By blocking this
downstream TCR signaling, calcineurin inhibitors (CNI) prevent
T-cell activation and downstream transcription of IL-2. Despite
the success of CNI in preventing acute rejection they cannot
fully control chronic immune activation leading to graft
dysfunction (5). Moreover, the use of CNI is associated with side
effects including cardiovascular and renal toxicities contributing
to patient’s morbidity (3). Alternatively, inhibition of the
classical NF-κB signaling pathway could be considered as an
immunosuppressive strategy.
NF-κB signal transduction is a key event in antigen-
dependent lymphocyte activation. In resting cells, NF-κB is
sequestered in the cytoplasm. TCR/BCR antigen engagement
results in the assembly of the caspase-recruitment domain
containing membrane-associated guanylate kinase 1 (CARMA1,
also known as CARD11), together with B-cell lymphoma 10
(Bcl-10) and mucosa-associated lymphoid tissue lymphoma
translocation gene 1 (Malt1) into the CBM complex (6, 7).
Malt1 is essential for NF-κB-dependent lymphocyte activation,
since Malt1-deficient (Malt1-ko) mice have defects in the
activation and proliferation of T and B cells, and suffer from
general immunodeficiency (8, 9). Malt1 can promote NF-κB
activation as a scaffold protein, by recruiting the ubiquitin
ligase tumor necrosis factor receptor-associated factor 6 (TRAF6)
that activates the inhibitor of κB (IκB) kinase (IKK) complex.
IKK-mediated phosphorylation of the NF-κB inhibitor, IκB,
promotes its proteasomal degradation. This allows NF-κB to
enter the nucleus and bind specific DNA sequences that control
the transcription of genes encoding key molecules involved
in inflammation, cell survival and division, including IL-2.
Malt1 also promotes T-cell activation and differentiation via its
proteolytic activity, by cleaving proteins such as A20 and RelB
that regulate NF-κB activation independently of IκB, and by
cleaving proteins such as Regnase-1 and Roquin that modulate
transcript stability (10–13).
Experimental models have reported up-regulation of NF-
κB activity in cardiac allografts at several time-points after
transplantation compared to control tissues (14, 15). Mice
with either CARMA1-deficiency or impaired T-cell specific
NF-κB signaling had reduced ability to reject allografts (16–
18). Interestingly, the induction of long-term allograft survival
in these mice was dependent on the type of transplanted
tissue. Indeed, whilst the impairment of NF-κB signaling
resulted in prolonged survival of heart allografts, it was not
sufficient to promote tolerance toward more immunogenic
skin allografts. Available immunosuppressive agents such as
steroids or proteasome inhibitors target NF-κB, but these drugs
are not cell-specific and could be associated with systemic
side-effects (19).
Here, we investigated whether more selective impairment of
NF-κB signaling, by specifically targeting Malt1, would prove
effective in promoting allograft survival. We report that Malt1-
deficiency attenuated Th1-mediated alloresponses in vitro and
in vivo, resulting in significantly prolonged MHC-mismatched
skin graft survival, even with very low frequencies of peripheral
CD4+Foxp3+ regulatory T cells (Treg). Additionally, Malt1-
deficieny induced tolerance to minor histocompatibility antigens
(minor-H)-mismatched skin grafts. Moreover, pharmacological
inhibition of Malt1 protease activity in wild-type mouse and
human T cells in vitro, regulated alloresponses without affecting
preexisting Treg. We therefore propose that in the setting of SOT,
targeting Malt1 could be an effective strategy to dampen immune
responses against MHC-mismatched allografts.
MATERIALS AND METHODS
Mice
Wild type (Wt) C57BL/6N (B6, H2b) and B6xDBA2 F1 (B6D2,
H2bxH2d) mice were purchased from Charles River and
Janvier Laboratories, France. Malt1-deficient mice (Malt1-
ko, C57BL/6N) were kindly provided by Vishva Dixit
(Genentech, San Francisco, CA, United States) (8). Malt1-
knock-in (Malt1-ki, C57BL/6-Malt1tmC472A) mice were
described (20). Experimental procedures were performed on
6–12 weeks old mice, in accordance with Canton de Vaud
veterinary authorizations (N◦ 2655.0), in specific pathogen-free
animal facilities.
Skin Transplantation
Full-thickness B6D2 or male B6 tail skins were grafted on
beds prepared on lateral flanks of sex-matched or female B6
recipients. Graft sites were protected under sterile gauze covered
by a plaster, removed at day 10. Grafts were observed daily
afterward and considered rejected when no viable skin remained.
For immunosuppression, mice were injected intraperitoneally
(i.p.) with 10 mg/kg cyclosporine (CsA; Sandimmun R©, Novartis
Pharma) once a day post-transplantation, or received mepazine
(Calbiochem) i.p. daily at 15 mg/kg, starting the day before
transplantation (21). All the in vivo experiments were repeated
at least 3 times.
Purification of Mouse T Cells
CD4+ T cells were negatively selected from mouse spleens
and lymph nodes single-cell suspensions after incubation
with the following rat anti-mouse hybridoma culture
supernatants: anti-MHC class II (M5/114, TIB-120/ATCC;
Manassas, VA, United States), anti-CD45R/B220 (RA3-3A1,
TIB-146/ATCC), anti-CD16/32 (2.4G2, HB-197/ATCC), anti-
CD8 (YTS169; Therapeutic Immunology Group, Oxford,
United Kingdom), followed by sheep anti-rat DynaBeads R©
(Invitrogen) before separation in a magnetic field. CD4+CD25−
and CD4+CD25+ subsets were selected using anti-CD25-
biotinylated (clone 7D4, BD Biosciences) monoclonal
antibody (mAb) followed by Streptavidin-MicroBeads R©
(MiltenyiBiotec, Germany) and separation on a magnetic
column (22).
Generation of Mouse Dendritic Cells
Fresh bone marrow (BM) cells flushed from femurs and tibias
were passed through 70-µm cell-strainers. After erythrocytes
lysis, BM cells were incubated with supernatants from
YTS169, YTS191, M5/114, RA3-3A1 followed by sheep anti-rat
Dynabeads R©. After magnetic separation, cells were transferred
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to 24-well plates in RPMI-10% FCS with 20 ng/ml mouse
recombinant granulocyte/macrophage colony-stimulating factor
(GM-CSF, R&D Systems), with change of medium and removal
of small non-adherent cells on days 2 and 4. For maturation,
1 µg/ml LPS (E. coli 026:B6, Sigma) was added on day 6
for the final 12 h.
Mouse Cell Cultures
All cultures were performed in RPMI-1640 (Sigma)
supplemented with 100 IU/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine, 0.01 M Hepes, 50 µM
2β-mercaptoethanol (Invitrogen) and 10% heat-inactivated
fetal calf serum (FCS) (EuroClone, United Kingdom). Purified
mouse T cells were stimulated with anti-CD3/CD28-coated
beads (Dynabeads R© Mouse T-Activator) at 1:1 bead-per-cell
ratio for 3 days. Alternatively, mixed leucocytes reactions
(MLR) were performed for 5 days, with 1:5 ratio of allogeneic
dendritic cells (DC) to T cells. T-cell proliferation was measured
by CFSE labeling (5 µM; Molecular probes, NL) and flow
cytometry analysis of CFSE dilutions. Wt T-cell proliferation
was also assessed in the MLR in the presence of the Malt1
tetrapeptide inhibitor z-VRPR-fmk [Bachem, Switzerland (23)]
or cyclosporine A (CsA; Sandimmun R©, Novartis Pharma). All
culture conditions were performed in triplicate wells.
Antibodies and Flow Cytometry
The following anti-mouse fluorochrome-conjugated mAbs and
respective isotype controls were used: CD4 (clone RM4-5),
CD8 (53-6.7), CD44 (IM7), CD62L (MEL-14), IL-2 (JES6-
5H4), IFN-γ (XMG1.2), IL-17 (TC11-18H10), CD25 (PC61)
and Foxp3 (FJK-16s) purchased from BD Biosciences and
eBioscience. For intracellular cytokines analysis, cells were re-
suspended at 2 × 106 cells/mL in RPMI-10% FCS, re-stimulated
with 50 ng/mL phorbol myristate acetate (PMA), 0.5 µg/mL
ionomycin for 5 h and 10 µg/mL Brefeldin A (Sigma). Cells
were then harvested, surface stained, fixed for 10′ in BD Facs
Lysing Solution, washed and permeabilized (Permeabilization
Buffer, Becton Dickinson AG) before intracellular staining.
For Foxp3, we used the Foxp3 staining kit (eBioscience). For
the analysis of p-Stat3 and p-Stat5 expression, T cells were
stimulated using anti-CD3/CD28-coated beads for 20′ at 37◦C.
Cells were then washed and permeabilized with pre-chilled Perm
Buffer III (BD Biosciences) for 30′ on ice, re-suspended in
FACS buffer and stained with BD PhosflowTM mAbs for 60′
at room temperature. Flow cytometry acquisition was done on
FACS-CaliburTM using CellQuestTM and analyzed using Flow
Jo software.
Isolation of Human Peripheral Blood
Mononuclear Cells
Blood samples were collected from healthy donors by the regional
transfusion center to prepare individual buffy coats. Peripheral
blood mononuclear cells (PBMC) were isolated from blood by
using Ficoll-Paque Plus (GE Healthcare) and density gradient
centrifugation. Antigen-presenting cells (APC) were enriched
from total PBMC, as previously reported (24).
Human Cell Cultures
APC were stimulated overnight using LPS (10 ng/ml) in complete
RPMI 1640 medium supplemented with 10% of fetal bovine
serum (FBS heat-inactivated, Euroclone), 0.01 M Hepes and non-
essential amino acids (NEAA 1X, GIBCO), 100 IU/ml penicillin
and 100 µg/ml streptomycin, 2 mM glutamate and pyruvate.
PBMC were co-incubated with enriched irradiated (30 Gy) APC
at a 1:2 responder/stimulator cells ratio, alone or with the
addition of different concentrations of mepazine hydrochloride
(CAS 738596-90-2, Calbiochem) a Malt1 inhibitor II, for 7 days
at 37◦C.
Flow Cytometry Analysis of Human Cells
At day 7 of co-culture, PBMC were harvested and briefly re-
stimulated with 50 ng/mL PMA, 0.5 µg/mL ionomycin and
10 µg/mL Brefeldin A, for 4 h at 37◦C for intracellular
cytokines detection. Dead cells were identified using the
LIVE/DEADTM Fixable Dead Cells kit (Invitrogen) following
the manufacturer’s instructions. The following anti-human
fluorochrome-conjugated Abs were used for surface and
intracellular labeling: CD3 (clone SK7), CD4 (SK3), CD25
(M-A251), CD127 (eBioRDR5), Foxp-3 (PCH101), Ki-67 (KI-
67), IL-2 (MQ1-17H12), IL-17 (BL168), IFNγ (B27). Abs
and corresponding isotype controls were purchased from
BD Biosciences, BioLegend and eBioscience. Flow cytometry
acquisition was done on a Gallios machine (Beckman Coulter)
and analyzed using Flow Jo software.
Statistical Analysis
Unpaired two-tailed Students t-test and one-way ANOVA
multiple comparison tests (GraphPad Prism version 6 software)
were used to calculate significance levels between experimental
groups. Median graft survival times (MST) between groups were
analyzed using Kaplan-Meier curves and the log-rank test. P
values <0.05 were considered significant.
RESULTS
Malt1-Deficiency Prolongs Survival of
MHC-Mismatched Skin Allografts by
Dampening the Production of
Pro-inflammatory Th1 Cytokines
Malt1-ko mice are characterized by the lack of IL-2 production
due to impaired downstream TCR signaling (8, 9). These mice
were described to have severely reduced frequencies of peripheral
Treg, similar proportions of single positive CD4 and CD8 T
cells as well as B cells, but with a different activation/memory
status in steady-state conditions, as compared to wild-type (Wt)
mice (20, 25). As Malt1-deficiency was shown to protect against
the development of experimental autoimmune encephalomyelitis
(EAE) despite diminished Treg numbers (26, 27), we tested
whether it could also protect against graft rejection in a skin
transplantation model. B6D2 donor skins were used as allografts
for Malt1-ko, control Wt B6 recipients and Wt B6 mice that were
treated with CsA (Figure 1A). Graft survival was significantly
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FIGURE 1 | Malt1-deficiency prolongs MHC-mismatched skin graft survival. (A) To evaluate the role of TCR signaling mediated via Malt1 in alloresponses, recipient
Malt1-ko and wild-type (Wt) B6 mice received a MHC-mismatched B6D2 skin allograft. As a comparison group, Wt mice were treated with cyclosporine A (CsA) i.p.
daily after transplantation. (B) Graft survival. Graft draining lymph nodes (dLN) were harvested at rejection and analyzed by flow cytometry. (C,D) Frequency of CD4+
and CD8+ T cells, respectively. (E,F) Mean fluorescence intensity (MFI) of CD44 on the surface of CD4+ and CD8+ T cells, respectively. (G–L) Detection of
intracellular cytokines after brief in vitro restimulation. (G,J) IFN-γ, (H,K) IL-2, (I,L) IL-17; in CD4+ and CD8+ T cells, respectively. n = 5 mice/group. MST, median
survival time.
prolonged in Malt1-ko mice (MST = 25 days, P < 0.001)
compared to Wt controls (MST = 14 days), while CsA treatment
alone had no significant effect on graft survival (MST = 15 days)
in this setting (Figure 1B).
Analysis of T-cell responses at the time of rejection in the
graft draining lymph nodes (dLN) indicated that, whilst Malt1-
deficiency and CsA treatment had no effect on the frequencies
of CD4+ and CD8+ T cells (Figures 1C,D), the activation status
(as reflected by the surface expression of CD44) of CD4+ but
not CD8+ T cells was significantly reduced in Malt1-ko mice
compared to both untreated control and CsA-treated Wt mice
(Figures 1E,F). Malt1-deficiency also significantly impaired the
production of IFN-γ and IL-2 effector cytokines by alloreactive
CD4+ and CD8+ T cells (Figures 1G–K). Surprisingly, the
frequency of CD4+IL-17+ T cells was augmented in Malt-ko
compared to Wt mice (Figure 1I). Interestingly, while CsA
treatment resulted in an expected diminished frequency of
alloreactive CD4+IL-2+ T cells, it had little effect on CD4+IFN-
γ+ and CD8+IL-2+ T cells and skewed the response toward
the expansion of CD8+IFN-γ+ and IL-17+ effector T cells
(Figures 1G–L). Taken together, these data indicated that unlike
CsA, Malt1-deficiency could effectively inhibit CD4+ Th1 and
CD8+ T-cell alloresponses, thus favoring the prolongation of
MHC-mismatched skin graft survival. However, similar to CsA
treatment, Malt1-deficiency resulted in the increased generation
of Th17 cells that most likely contributed to final, albeit delayed,
graft rejection.
Allograft Rejection in Malt1-ko Mice
Correlates With a Lack of Peripheral Treg
and Elevated IL-17+ Effector T Cells
Early After Transplantation
Although Malt1-ko mice had prolonged graft survival compared
to controls, the skin grafts were all, eventually, rejected. To
further dissect the mechanisms leading to rejection, we compared
T-cell responses in the graft dLN (Figure 2) and spleen
(Supplementary Figure 1) of Malt1-ko and Wt recipients of
B6D2 skins on days 7 and 10 post transplantation. The frequency
of Treg remained lower in Malt1-ko in comparison to Wt
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FIGURE 2 | Allograft rejection in Malt1-ko mice correlates with a lack of peripheral Treg and elevated IL-17-producing T cells early after transplantation. Graft draining
lymph nodes (dLN) of wild-type (Wt) B6 and Malt1-ko recipients were analyzed by flow cytometry at days 7 and 10 post transplantation of B6D2 skins. Frequency of
(A) CD4+Foxp3+ T cells. (B,C) Mean fluorescence intensity (MFI) of CD44 and CD62L expression on the surface of CD4+ and CD8+ T cells, respectively. (D–G)
Detection of intracellular cytokines after brief in vitro restimulation. (D,E) IFN-γ, (F,G) IL-17; in CD4+ and CD8+ T cells, respectively. n = 5 mice/group.
mice, even if it tended to increase over time after immune
activation (Figure 2A). As compared to their Wt counterparts,
CD4+ T cells in Malt1-ko mice were less activated by day
10, while paradoxically, CD44 was significantly upregulated
on CD8+ T cells early after transplantation (Figures 2B,C).
Malt1-deficiency impaired the early differentiation of CD4+
and CD8+ T cells into IFN-γ producing effector cells in
response to an allograft (Figures 2D,E), but promoted the
differentiation of IL-17-producing effector T cells by day 7 and
day 10 for CD4 or CD8 T cells, respectively (Figures 2F,G).
Collectively, these data suggested that whilst Malt1-deficiency
impaired the differentiation of alloreactive Th1 and CD8+IFN-
γ+ T cells, insufficient peripheral Treg numbers early after
transplantation and a skewing toward IL-17-mediated immune
responses triggered rejection.
Malt1-Deficiency Promotes Tolerance to
Minor Histocompatibility
Antigens-Mismatched Skin Grafts
We hypothesized that the immunosuppression provided by
Malt1-deficiency may be sufficient to promote graft tolerance
in response to a weaker allogeneic stimulation and thus used a
MHC-matched but minor-H-mismatched donor-recipient strain
combination. Female Malt1-ko, Wt and CsA-treated Wt B6
mice were transplanted with male B6 donor skins (Figure 3A).
Female Malt1-ko recipients were tolerant to male donor skins
(MST > 100 days) (Figure 3B). Intriguingly, CsA was deleterious
in this setting, by accelerating rejection in Wt and breaking
tolerance in Malt1-ko recipients, when compared to non-treated
Wt mice (MST = 23, 15, and 30 days in Wt + CsA, Malt1-
ko + CsA and non-treated Wt, respectively). We next analyzed
the peripheral effector T-cell repertoire in the graft dLN at
rejection or at day 100 for the tolerant mice. Consistent with
their genetic defect, Malt1-ko mice had a reduced population
of peripheral Treg compared to Wt rejectors (Figures 3C,D).
Exposure to CsA resulted in similar low frequencies of peripheral
Treg; however, CD44 was upregulated on CD4+ and CD8+ T
cells (both in Wt and Malt1-ko CsA-treated mice), reflecting
the presence of a population of activated T cells that could
have promoted acute rejection (Figures 3E,I). Malt1-deficiency
was sufficient to prevent the activation and production of pro-
inflammatory cytokines by CD4+ and CD8+ T cells in response
to minor-H alloantigens, thus promoting tolerance despite low
Treg frequencies. In comparison, CsA treatment also resulted in
reduced frequencies of IL-2+ effector T cells, but it could not
control IFN-γ+ effectors or CD4+IL-17+ T cells (Figures 3F–
H,J–L). Therefore, these data indicated that CsA accelerated
minor-H-mismatched grafts rejection in both Wt and Malt1-
ko mice by augmenting the numbers of effector CD8+IFN-γ+
and pathogenic CD4+IL-17+ T cells. These data were further
confirmed by analyzing the kinetics of T-cell activation as well
as Treg frequencies in the peripheral blood at different time-
points after transplantation. In both Wt and Malt1-ko mice, we
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FIGURE 3 | Malt1-deficiency promotes tolerance to minor histocompatibility antigens-mismatched skin grafts. (A) Male B6 skins were transplanted to wild-type (Wt)
and Malt1-ko female B6 mice that were left untreated or received cyclosporine A (CsA) i.p. daily after transplantation. (B) Graft survival. (C,D) Frequency of
CD4+CD25+ and CD4+Foxp3+ T cells, respectively. (E,I) Mean fluorescence intensity (MFI) of CD44 on the surface of CD4+ and CD8+ T cells, respectively. (F–L)
Detection of intracellular cytokines after brief in vitro restimulation. (F,J) IFN-γ, (G,K) IL-2, (H,L) IL-17; in CD4+ and CD8+ T cells, respectively. n = 5 mice/group.
MST, median survival time.
observed a progressive increase from day 6 to day 15 of the
activation marker CD44 on CD4+ and CD8+ T cells upon CsA
treatment, compared to the untreated controls (Figures 4A,B).
CsA exposure also strikingly decreased the number of Treg in
Wt mice, and to a lower extent, in Malt-ko mice that already had
constitutively reduced Treg levels (Figures 4C,D).
Constitutive Inhibition of Malt1 Protease
Activity as in Malt1-ki Mice Allows Only
Partial Prolongation of
MHC-Mismatched Skin Allograft Survival
We next wanted to evaluate the selective contribution of Malt1
protease activity in controlling alloresponses. To this purpose,
we performed transplantation experiments in Malt1-ki mice
expressing a catalytically inactive mutant of Malt1 that conserves
its scaffold function (Figure 5A). Constitutive inhibition of Malt1
protease activity, as in Malt1-ki B6 recipients, allowed only slight
prolongation of the survival of B6D2 skin allografts compared
to Wt B6 recipients (MST = 18.5 and 15.5 days in Malt-ki and
Wt, respectively. P = 0.003) and Malt-ko mice (MST = 25 days)
(Figure 5B). This limited effect was consistent with our previous
report, describing an intrinsic default in Treg development
combined with only partially compromised T-cell activation
capacity in Malt-ki mice, resulting in an imbalance between
Treg and effector T cells (20). Indeed, in addition to a reduced
frequency of Treg, we observed remarkably elevated CD4+
and CD8+ effector T-cell responses in Malt1-ki at rejection,
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FIGURE 4 | Cyclosporine A treatment gradually decreases peripheral Treg whilst increasing activated effector T cells in Wt and Malt1-ko mice. Male B6 skins were
transplanted to wild-type (Wt) and Malt1-ko female B6 mice that were left untreated or received cyclosporine A (CsA) i.p. daily after transplantation. The recipient
mice were tail-bled the day before transplantation (d-1), then at day 6 and 15 post transplantation. (A,B) Mean fluorescence intensity (MFI) of CD44 expression on
the surface of CD4+ and CD8+ T cells, respectively. (C,D) Frequency of CD4+CD25+ and CD4+Foxp3+ T cells. n = 5 mice/group.
compared to Wt recipients (Figures 5C–F). Thus, transplantation
tolerance was impaired in mice with constitutive inactivation of
the enzymatic activity of Malt1.
Selective Inhibition of Malt1 Protease
Activity in Wt Peripheral T Cells
Maintains Treg and Attenuates Th17
Differentiation in Response to
Alloantigens in vitro
We further investigated whether selectively inhibiting the
protease activity of Malt1 in Wt peripheral mature T cells,
utilizing the Malt1 tetrapeptide inhibitor z-VRPR-fmk (MI)
(23), would result in a better targeting of effector T cells,
while preserving peripheral Treg function. Purified whole T
cells from B6 Wt and Malt1-ko mice, as well as Wt T cells
treated in vitro with either MI or CsA, were cultured with
allogeneic B6D2 DC and analyzed after a 6-days MLR. Malt1-
deficiency, MI and CsA treatments, all significantly decreased
the proliferative capacity of CD4+ and CD8+ T cells in vitro in
response to alloantigens (Figure 6). Complete Malt1-deficiency
most effectively inhibited the proliferation of CD4+ T cells
compared to MI and CsA, while CsA was more effective on
the proliferation of CD8+ T cells (Figure 6A). CsA treatment
resulted in strongly reduced proportions of CD4+CD25+Foxp3+
T cells at the end of the co-culture. In contrast, MI treatment
did not significantly affect the in vitro expansion of Treg in the
MLR, compared to untreated Wt T cells (Figure 6B). Similar to
the in vivo data, Malt1-deficiency impaired the differentiation of
CD4+IFN-γ+ Th1 cells when compared to control Wt T cells,
while the expression of the Th17 transcription factor ROR-γt
and the frequency of CD4+IL-17+ T cells were dramatically
elevated. MI treatment of Wt T cells less effectively inhibited Th1
cells, but at the same time did not increase Th17 differentiation
(Figures 6C–E). Overall, in contrast to full Malt1-deficiency or
CsA treatment, selective inhibition of Malt1 protease activity in
peripheral Wt T cells maintained Treg whilst attenuating Th17
differentiation in vitro.
We next assessed the effects of MI treatment on TCR
downstream IL-2-dependent signaling, as it critically influences
the differentiation of T helper subsets and is required for the
maintenance and function of Treg (28, 29). We thus analyzed
signal transducer and activator of transcription (Stat)3 and
Stat5 activation after brief in vitro stimulation of T cells. Our
data showed that Malt1-ko and CsA-treated T cells, both of
which promoted the differentiation of Th17 cells, had slightly
increased phosphorylated (p)-Stat3 but significant low p-Stat5
levels (Figure 6F). In comparison, Wt and MI-treated T cells
in which the subset of CD4+Foxp3+ T cells was maintained in
the alloMLR, had a higher expression of p-Stat5. Collectively,
these data were consistent with the fact that selective inhibition
of Malt1 protease activity in mature T cells, in contrast to Malt1-
deficiency or CsA treatment, maintains Treg frequencies while
attenuating Th17 differentiation.
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FIGURE 5 | Constitutive inhibition of Malt1 protease activity in Malt1-ki mice only slightly delays graft rejection. (A) Recipient Malt1-ki, Malt1-ko and Wt B6 mice
received a MHC-mismatched B6D2 skin graft. (B) Graft survival. CD4+ and CD8+ T-cell responses in the graft draining LN (dLN) were analyzed by flow cytometry.
(C) Mean fluorescence intensity (MFI) of CD44 expression on the surface of CD4+ and CD8+ T cells. Frequency of (D) CD4+CD25+Foxp3+ T cells, (E) IFN-γ+
CD4+ and CD8+ T cells, (F) IL-17+ CD4+ T cells. n = 4–6 mice/group. MST, median survival time.
The Malt1 Protease Inhibitor Mepazine
Regulates Human T Cells Alloresponse
in vitro and Prolongs MHC-Mismatched
Skin Allograft Survival in Wild-Type Mice
Next, we wanted to evaluate the potential of selective targeting
of Malt1 protease activity in clinical transplantation. We tested
the effect of mepazine hydrochloride, a clinically approved drug
for psychological disorders, which was later shown to be a potent
cell-permeable inhibitor of Malt1 protease (30). PBMC isolated
from healthy volunteers were cultured for 7 days in the presence
of allogeneic irradiated APC, without or with the addition
of mepazine. Mepazine treatment significantly decreased the
proliferation of human CD4+ and CD8+ T cells (Figure 7A) in
the alloMLR. Importantly, the inhibition of Malt1 by mepazine
did not affect the frequency of the CD4+CD25+ CD127−Foxp3+
T cell population at the end of the co-culture (Figure 7B). While
the drug did not significantly reduce the production of IFN-
γ in both CD4+ and CD8+ T cells in our culture conditions
(Figure 7C), we observed a significant decrease in the frequency
of IL-2+ CD4+ and CD8+ T cells (Figure 7D) and CD4+IL-
17+ T cells (Figure 7E). Therefore, selective targeting of Malt1
protease in human PBMC sustains Foxp3+ Treg cells and impairs
Th17 differentiation during alloresponses in vitro. Finally, when
used in vivo in our transplantation model (Figure 7F), mepazine
prolonged allograft survival in Wt B6 recipients of B6D2 skin
grafts (MST = 19 and 14.5 days in mepazine-treated and non-
treated, respectively, P = 0.002). The prolongation of graft
survival was significant when compared to the use of CsA
(MST = 15 days, Figure 1B) in the same experimental setting and
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FIGURE 6 | Selective inhibition of Malt1 protease activity in Wt peripheral T cells does not affect Treg but attenuates Th17 differentiation in an alloresponse. Whole T
cells (TC) were purified from spleen and lymph nodes of wild-type (Wt) and Malt-ko B6 mice. 1 × 105 CFSE-labeled responder T cells were cultured with 0.2 × 105
allogeneic B6D2 DC for 6 days. Wt T cells cultured alone in medium were used as controls (Wt Nil). As comparison, Wt T cells were treated with either 200 µM Malt1
tetrapeptide inhibitor z-VRPR-fmk (MI), or 100 ng/ml cyclosporine A (CsA). (A) CFSE dilutions of dividing CD4+ (upper gate) and CD8+ (lower gate) T cells on day 6
of culture. Frequency of (B) Foxp3+CD25+, (C) ROR-γt+, (D) IL-17+ and (E) IFN-y+ CD4+ T cells (gated on CD4+), respectively. (F) Phosphorylated (p)-Stat3 and
p-Stat5 expression (gated on CD4+) analyzed by flow cytometry after short restimulation of T cells with anti-CD3/CD28-coated beads at 37◦ for 20 min. All culture
conditions were performed in triplicate. Flow cytometry dot-plots and histograms data are representative of one out of three independent experiments.
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FIGURE 7 | The Malt1 protease inhibitor mepazine regulates human T cells alloresponse in vitro and prolongs MHC-mismatched skin allograft survival in wild-type
mice. PBMC from healthy donors were cultured alone (CTRL, left dot-plot panels) or co-cultured with irradiated allogeneic APC in a MLR, without or with the Malt1
inhibitor mepazine (MI, 3 µg/ml) (MLR and MLR + MI, middle panel and right panel dot-plots, respectively). Cells were harvested on day 7 of co-culture and analyzed
by flow cytometry (A) CD4 (upper gate) and CD8 (lower gate) T cells proliferation was assessed by Ki-67 staining. Frequency of (B) CD4+CD25+CD127-Foxp3+ T
cells, (C) IFN-y+, (D) IL-2+ and (E) IL-17+ CD4+ (upper gate) and CD8+ (lower gate) T cells, respectively. All culture conditions were performed in triplicates. Flow
cytometry data are representative of one out of three independent experiments. Means with SD, *P < 0.05. (F) Recipient wild-type (Wt) B6 mice received a
MHC-mismatched B6D2 skin allograft, and were left untreated or received mepazine i.p. daily, starting the day before transplantation. Graft survival was monitored
daily. MST, median survival time.
Frontiers in Immunology | www.frontiersin.org 10 September 2020 | Volume 11 | Article 576651
fimmu-11-576651 September 10, 2020 Time: 19:36 # 11
Govender et al. Targeting Malt1 to Prevent Rejection
interestingly similar to the graft survival obtained in Malt-ki B6
mice (MST = 18.5 days, Figure 5B).
DISCUSSION
Immunotherapeutic strategies targeting alloantigen-activated T
cells remain the cornerstone of current immunosuppressive
management after SOT (3) and our study analyzed for the first
time the role of Malt1-dependent TCR downstream signaling in
an experimental model of allogeneic transplantation. Consistent
with studies in other models (8, 9, 20, 27), Malt1-deficiency
attenuated alloreactive Th1 responses resulting in prolonged
survival of MHC-mismatched skin allografts, despite very low
frequencies of peripheral Treg in these mice (25). However,
tolerance was not achieved in our experimental setting and
we observed a progressive increase in IL-17-producing T
cells after transplantation and at rejection. Since Malt1-ko
mice have impaired B-cell development and reduced antibody
production (8, 9), we propose that Th17 cells played a key
role in mediating late rejection. In the same experimental
setting, mice treated with the CNI CsA were not protected
and rejected their grafts with similar kinetics as Wt recipients.
As compared to Malt1-ko, IFN-γ+ and IL-17+ effector T cells
were increased at rejection in CsA-treated recipients. Thus, our
data suggest the superiority of targeting Malt1 in preventing
the activation of alloreactive T cells and acute rejection of
MHC-mismatched grafts.
Graft rejection has been associated with a predominant Th1
response. It was previously described that in the absence of
a functional Th1 pathway, as in T-bet−/− mice, Th17 cells
could cause allograft rejection (2). In clinical studies of kidney
and lung transplantation, elevated levels of IL-17 mRNA or
protein were associated with accelerated graft rejection (31).
In line with these data, we report that while impeding Th1
activation and IL-2 production, CsA treatment and Malt1-
deficiency resulted in elevated IL-17+ T cells after allogeneic
skin transplantation. The elevated IL-17 response observed in
Malt1-ko mice after transplantation is in contrast to some
reports that described the requirement of Malt1, and in
particular of its protease activity, for Th17 differentiation (12,
13). Because TCR-downstream canonical NF-κB activation is
blunted by Malt1-deficiency, our findings suggest that in some
settings, such as during an alloresponse and in an inflammatory
microenvironment, Th17 differentiation could be promoted in
Malt1-ko mice via an alternative T-cell signaling pathway. Indeed,
the ERK-MAPK pathway was reported to contribute to the
regulation of the reciprocal differentiation between Treg and
Th17 cells in autoimmunity models such as EAE and colitis
(32). Whether the ERK-MAPK or other non-canonical NF-
κB signaling pathways were up-regulated and played a role
in increased Th17 differentiation in our transplantation model
remains to be investigated (32, 33). Finally, we observed increased
CD8+IL-17+ T cells (Tc17) in Malt1-ko and CsA-treated mice
after allogeneic transplantation. Although unconventional in the
alloresponse, Tc17 have been reported to contribute together with
CD4+IL-17+ T cells to the induction of EAE in the absence
of Treg (34). Taken together, our results suggest that Malt1-
deficiency and CsA treatment both resulted in the reduced
frequency of peripheral Treg and impaired Th1 responses, but
promoted the differentiation of Th17 cells that mediated allograft
rejection.
In an experimental transgenic mouse model targeting the
CBM complex of NF-κB activation, it was shown that whilst
defective NF-κB intrinsic signaling in T cells promoted long-
term cardiac allograft survival, more immunogenic primary
skin allografts where rejected (17). We therefore investigated
whether immunosuppression provided by Malt1-deficiency was
sufficient to promote graft tolerance in a weaker alloresponse.
We found that Malt1-deficiency induced robust tolerance to
minor-H-mismatched skin grafts and, even with low peripheral
Treg numbers, was sufficient to reduce the activation and pro-
inflammatory cytokines production of alloreactive CD4+ and
CD8+ T cells. CsA treatment however, significantly reduced
graft survival of both Wt and Malt1-ko mice in this donor-
recipient strain combination (35, 36), further highlighting
different mechanisms of regulation of TCR downstream signaling
by calcineurin and Malt1. We observed that CsA treatment
progressively decreased the frequency of peripheral Treg in both
Wt and Malt1-ko mice. Furthermore, as opposed to Malt1-
deficiency, CsA treatment could not efficiently control the
activation of alloreactive CD4+ and CD8+ T cells, resulting in a
skewed response toward effector CD8+IFN-γ+ and pathogenic
CD4+IL-17+ T cells in the absence of IL-2 signaling. The
combined inhibition of NFAT and NF-κB signaling by treating
Malt1-ko mice with CsA further decreased Treg numbers
and augmented effector responses resulting in accelerated
allograft rejection. Taken together, these results indicated that
targeting Malt1 offered some advantages over the use of CsA
as immunosuppressive strategy after transplantation, but also
indicates that combined treatment offers no additional benefit.
Following on our results in Malt1-ko mice, we investigated
how selectively targeting the protease activity of Malt1 would
affect alloresponses. As previously reported, we confirmed
excessive immune activation in Malt1-ki adult mice in response
to an allograft, associated with an intrinsic T-cell developmental
defect (including thymus-derived Treg) and dysregulated
immune balance between Treg and effector T cells (20, 25,
37–40). Because of the known in vivo toxicity of the fmk
component of the Malt1 protease selective inhibitor z-VRPR-
fmk (MI), we used an in vitro model to test the effect of MI
on mature peripheral T cells (23). In comparison to complete
Malt1-deficiency and CsA treatment, MI treatment of Wt
peripheral mouse T cells attenuated T-cell proliferation in
response to alloantigens, while the subset of preexisting Treg
was not affected and Th17 responses were not promoted.
Stat3 and Stat5 activation were reported to play a key role in
the reciprocal balance between Treg and Th17 cells. Indeed,
TCR-induced IL-2-mediated activation of Stat5 promotes the
maintenance and suppressive function of Foxp3+ Treg and
limits the responsiveness of T cells to IL-6 (28, 41, 42). Activated
p-Stat5 also competes with p-Stat3 for binding to the IL-17 gene
locus, preventing Th17 cell differentiation (28, 29, 43). Thus,
the inhibition of IL-2 signaling (and Stat5) in Malt1-ko and
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after CsA treatment would promote Stat3 usage and shift the
cells toward Th17 differentiation. Accordingly, flow cytometry
analysis revealed elevated Th17 responses in Malt1-ko and
CsA-treated alloreactive T cells, which corresponded to increased
p-Stat3 and decreased p-Stat5 expression in comparison to Wt
and MI-treated Wt T cells. These data further supported our
in vivo findings that had shown enhanced Th17 responses in
Malt1-ko and CsA-treated transplant recipients.
Finally, in the perspective of clinical application, we explored
the effect of selective targeting of Malt1 protease activity
in regulating human PBMC alloresponses. We chose to use
mepazine, a drug already available in the clinic and with a known
safety profile. Besides their indication as antipsychotic drugs,
phenothiazine derivatives such as mepazine were shown to be
potent selective small molecule inhibitors of Malt1 protease (44,
45). Mepazine was successfully tested as a therapy in Malt1-
dependent tumor models (21, 30, 46) as well as in EAE (27,
47). In our experimental in vitro setting using human PBMC,
mepazine treatment attenuated T-cell proliferation in response
to alloantigens in 7-days MLRs, without promoting Th17
differentiation. Importantly, preexisting Treg were not negatively
affected despite decreased frequencies of IL-2+ effector T cells.
Based on these encouraging in vitro data, we explored the
effect of mepazine treatment in our in vivo transplantation
model. In initial experiments, mepazine slightly improved MHC-
mismatched allograft survival in Wt B6 recipients, in a setting
where CsA treatment has no beneficial effect. Interestingly, the
effect was similar to the extent of graft survival prolongation
observed in Malt-ki mice. Further studies are however needed
to confirm the therapeutic potential of mepazine and other
available selective Malt1 protease inhibitors in transplantation.
First, we have to define the optimal dose and duration of
mepazine treatment in our transplantation model. Second,
the effect of mepazine may be optimized if combined with
other immunomodulatory drugs, in order to control the clonal
expansion of alloreactive effector T cells and preserve (or expand)
the pool of allospecific Treg, as suggested by our previous
experimental data (5, 48).
Besides mepazine, potent selective Malt1 paracaspase
pharmacologic inhibitors have been described that may also be
suited in the setting of solid organ transplantation (44, 49–51).
The efficacy/safety profile of these compounds need to be tested
in our experimental model, in particular regarding the effect of
prolonged use on the pool of effector and regulatory immune cell
subsets. Indeed, unless tolerance to alloantigens can be induced,
life-long immunosuppressive therapy is required after SOT. In
this regard, a recent preclinical study has revealed potential safety
issues regarding prolonged in vivo Malt1 protease inhibition,
in particular regarding the deleterious effect on peripheral
Treg (51). In the study, the authors show that as opposed to
mepazine, the chronic administration of a novel potent inhibitor
induced a dose-dependent reduction in Treg with associated
autoimmunity, reminiscent of the Malt-ki mice. Therefore, less
potent Malt1 protease inhibition as achieved with mepazine, or
less selective Malt1 inhibition may prove to be better strategies
to preserve Treg homeostasis in autoimmune diseases and after
SOT. Finally, data suggest Malt1-independent therapeutic effects
of mepazine in inflammatory disease models that may also prove
beneficial in transplantation (52).
In summary, our study highlights the potential but also
the possible limitations of targeting Malt1 (either scaffold
or protease) in allogeneic responses. We propose that, in
the context of solid organ transplantation, targeting Malt1
signaling may prove as an advantageous alternative to CNI
in immunosuppressive protocols. Furthermore, combination
therapies including the administration of a selective inhibitor of
Malt1 protease activity might offer a better control of alloreactive
Th1 responses while preserving preexisting Treg in the peripheral
T-cell pool, and without promoting Th17 differentiation.
Therefore, besides current developments in the field of oncology,
there is the need for research and validation in solid organ
transplantation of selective Malt1 inhibitors that can be safely
used as part of immunosuppressive protocols in the clinic.
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